argenx is a rare biotech that became a profitable immunology powerhouse—now it must defend VYVGART in the FcRn Wars while MMN is the critical second act.
Overview
argenx has emerged as a global immunology leader by commercializing a first-in-class FcRn blocker, VYVGART, built on its camelid-antibody innovation heritage and the Immunology Innovation Program (IIP) discovery/partnering model. By late 2025 the company reached a major inflection: it transitioned from clinical-stage biotech to sustainably profitable commercial entity, driven by explosive VYVGART growth in gMG and successful expansion into CIDP. Q3 2025 net product sales reached ~$1.13B with operating profit of ~$346M and a strong cash position of ~$4.3B, giving the company freedom to fund multiple Phase 3 programs and pursue business development. The strategy (“Vision 2030”) targets 50k patients, 10 labeled indications, and 5 new molecular entities in Phase 3, but the story has become more complex: FcRn competition intensified with J&J’s nipocalimab approval and Immunovant’s IMVT-1402 development, and the December 2025 TED setback undermined the assumption FcRn will translate broadly across all IgG diseases.